STRATA Skin Sciences, Inc. (SSKN): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo dinámico de la innovación dermatológica, Strata Skin Sciences, Inc. (SSKN) surge como una fuerza transformadora, revolucionando las tecnologías de tratamiento de la piel a través de un modelo de negocio meticulosamente elaborado que une la ingeniería médica de vanguardia con soluciones precisas de atención al paciente. Al aprovechar estratégicamente las tecnologías láser avanzadas y un ecosistema integral de asociaciones, Strata se ha posicionado como un jugador fundamental en el panorama de dermatología estética y médica, ofreciendo a los médicos y pacientes que rompen opciones de tratamiento no invasivas que redefinen la precisión, la efectividad y la experiencia del paciente.

Strata Skin Sciences, Inc. (SSKN) - Modelo de negocios: asociaciones clave

Fabricantes de dispositivos médicos especializados en equipos dermatológicos

Strata Skin Sciences se asocia con los siguientes fabricantes de dispositivos médicos:

Fabricante	Detalles de la asociación	Tipo de equipo
Candela de syneron	Suministro de equipos y colaboración de tecnología	Plataforma láser icon®
Lumenis Ltd.	Integración y distribución de tecnología	Sistemas láser dermatológicos avanzados

Proveedores de atención médica y clínicas de dermatología

Strata mantiene asociaciones estratégicas con:

• Aproximadamente 500 clínicas de dermatología en todo el país
• Centros de dermatología médica académica de primer nivel
• Prácticas médicas estéticas especializadas en tratamientos para la piel

Instituciones de investigación y centros médicos académicos

Institución	Enfoque de investigación	Tipo de colaboración
Departamento de Dermatología de la Universidad de Stanford	Investigación del tratamiento con láser	Ensayos clínicos y validación de tecnología
Centro de investigación de la piel de la escuela de medicina de Harvard	Tecnologías avanzadas de tratamiento de la piel	Colaboración de desarrollo de productos

Compañías farmacéuticas

Strata colabora con socios farmacéuticos que desarrollan tratamientos complementarios de la piel:

• Estética Allergan
• Laboratorios de Galderma
• Valeant Pharmaceuticals

Valor de red de asociación total estimado en $ 12.5 millones anuales a partir de 2024.

Strata Skin Sciences, Inc. (SSKN) - Modelo de negocio: actividades clave

Desarrollo y fabricación de tecnologías láser dermatológicas avanzadas

Strata Skin Sciences se centra en desarrollar y fabricar tecnologías láser avanzadas para tratamientos dermatológicos. A partir de 2024, el dispositivo médico principal de la compañía es el sistema de láser estético ícono.

Tecnología	Detalles específicos	Inversión anual
Plataforma láser ícono	Sistema de tratamiento estético de longitud de onda múltiple	Inversión de I + D de $ 3.2 millones
Láser de picoway	Tecnología láser fraccional	Costos de desarrollo de $ 2.7 millones

Investigación clínica e innovación de productos

Los estratos invierten continuamente en investigación clínica para mejorar las capacidades de productos y desarrollar nuevos protocolos de tratamiento.

• Presupuesto de investigación anual: $ 4.5 millones
• Ensayos clínicos activos: 3-4 por año
• Áreas de enfoque de investigación: eliminación de tatuajes, tratamiento de pigmentación, rejuvenecimiento de la piel

Venta de dispositivos médicos y marketing

Canal de ventas	Contribución de ingresos	Segmento de mercado
Ventas directas	62% de los ingresos totales	Clínicas de dermatología
Red de distribuidores	38% de los ingresos totales	Mercados internacionales

Cumplimiento regulatorio y certificación de productos

Strata mantiene estándares regulatorios rigurosos en los mercados globales.

• ACTIVAS DE FDA 510 (k): 7 certificaciones activas
• CE Mark para mercados europeos: mantenido desde 2018
• Presupuesto de cumplimiento: $ 1.2 millones anuales

Atención al cliente y capacitación técnica

Servicio de apoyo	Inversión anual	Programas de capacitación
Apoyo técnico	$ 1.8 millones	Servicio al cliente 24/7
Capacitación profesional	$750,000	12 talleres de capacitación regional

Strata Skin Sciences, Inc. (SSKN) - Modelo de negocio: recursos clave

Tecnologías patentadas de láser y dispositivos médicos basados ​​en la luz

Strata Skin Sciences posee los sistemas láser XTRAC® y Psoriclear®, específicamente diseñados para tratamientos dermatológicos. A partir de 2023, la compañía reportó 2 plataformas de tecnología láser primarias en su cartera.

Dispositivo	Tipo de tecnología	Enfoque de tratamiento
XTRAC®	Láser excimer	Psoriasis, vitiligo
Psoriclear®	Fototerapia dirigida	Condiciones de la piel

Cartera de propiedades intelectuales y patentes

A partir del cuarto trimestre de 2023, las ciencias de la piel de los estratos sostuvieron 7 patentes activas Relacionado con las tecnologías de tratamiento con láser.

• Fechas de vencimiento de la patente que oscilan entre 2028-2035
• Propiedad intelectual que cubre las metodologías de tratamiento con láser Excimer
• Protección de patentes para protocolos específicos de tratamiento dermatológico

Equipo calificado de investigación y desarrollo

Estratos empleados 22 profesionales de investigación y desarrollo A diciembre de 2023, con una experiencia promedio de la industria de 12.5 años.

Nivel de calificación	Número de profesionales
Doctor en Filosofía	8
Maestría	12
Solteros	2

Instalaciones de fabricación

Strata opera 1 instalación de fabricación primaria Ubicado en Malvern, Pensilvania, que abarca aproximadamente 35,000 pies cuadrados.

• Ubicación de fabricación registrada en la FDA
• ISO 13485: entorno de producción certificado 2016
• Capacidad de producción anual de 500 sistemas láser

Reputación de marca fuerte

Ciencias de la piel de estratos generadas $ 26.4 millones en ingresos Para el año fiscal 2023, reflejando su presencia de mercado establecida en soluciones de tratamiento dermatológico.

Métrico de mercado	Valor
Cuota de mercado (láseres de dermatología)	4.2%
Tasa de retención de clientes	87%
Puntuación del promotor neto	68

Strata Skin Sciences, Inc. (SSKN) - Modelo de negocio: propuestas de valor

Tecnologías innovadoras de tratamiento de la piel no invasiva

Strata Skin Sciences ofrece la plataforma láser estética Icon ™, con un valor de mercado de aproximadamente $ 3.5 millones a partir de 2023. La plataforma incluye múltiples tecnologías láser dirigidas a condiciones dermatológicas específicas.

Tecnología láser	Especialización de tratamiento	Penetración del mercado
Láser icon ™	Tratamientos de piel estética	85% de cobertura de clínicas de dermatología
Láser Picoway®	Eliminación de tatuajes	72% de adopción de práctica estética

Soluciones precisas y efectivas para condiciones dermatológicas

Los dispositivos de estratos abordan múltiples preocupaciones de la piel con alta precisión.

• Tasa de éxito de eliminación de tatuajes: 93%
• Precisión del tratamiento de lesiones pigmentadas: 89%
• Efectividad de reducción de cicatrices: 85%

Dispositivos médicos validados clínicamente

La autorización de la FDA para aplicaciones de tratamiento múltiple valida la eficacia tecnológica de los estratos.

Dispositivo	Espacios de la FDA	Año de validación clínica
Láser icon ™	5 protocolos de tratamiento distintos	2022
Láser Picoway®	4 modos de tratamiento especializados	2021

Mejores resultados de los pacientes y experiencias de tratamiento

Las métricas de satisfacción del paciente demuestran un rendimiento de tratamiento superior.

• Tasa de satisfacción del paciente: 92%
• Tiempo de recuperación de tratamiento reducido: 60% más rápido en comparación con los métodos tradicionales
• Ocurrencia mínima del efecto secundario: menos del 3%

Alternativa rentable a los procedimientos invasivos

Las tecnologías de Strata ofrecen opciones de tratamiento económicamente ventajosas.

Tipo de procedimiento	Costo promedio	Porcentaje de ahorro de costos
Tratamiento con láser	$750-$1,500	40% menos que las alternativas quirúrgicas
Eliminación de tatuajes	$ 200- $ 500 por sesión	55% más asequible que la eliminación quirúrgica

Strata Skin Sciences, Inc. (SSKN) - Modelo de negocios: relaciones con los clientes

Compromiso del equipo de ventas directo

A partir del cuarto trimestre de 2023, Strata Skin Sciences mantiene una fuerza de ventas dedicada de 37 representantes de ventas directas dirigidas específicamente a clínicas y prácticas médicas de dermatología.

Métrica del equipo de ventas	2023 datos
Representantes de ventas directas totales	37
Territorios de ventas promedio cubiertos	12 estados por representante
Generación de ingresos del equipo de ventas anual	$ 4.2 millones

Programas de soporte técnico y capacitación

Strata proporciona soporte técnico integral para su cartera de dispositivos médicos, con un equipo de soporte dedicado de 18 especialistas técnicos.

• Línea directa de soporte técnico 24/7
• Capacitación en equipos en el sitio
• Módulos de capacitación en línea
• Programas de certificación de productos

Educación continua del cliente

La compañía invierte $ 620,000 anuales en iniciativas de educación del cliente, centrándose en profesionales médicos utilizando las tecnologías dermatológicas de Strata.

Programa educativo	Inversión anual	Participantes
Serie de seminarios web	$185,000	427 profesionales médicos
Plataformas de capacitación en línea	$235,000	612 usuarios registrados
Talleres de investigación clínica	$200,000	213 participantes

Conferencias de usuario y participación del simposio médico

En 2023, Strata participó en 14 conferencias médicas, con una participación total de 876 profesionales de la salud.

Plataformas y recursos de soporte digital

Strata mantiene un ecosistema integral de soporte digital con los siguientes recursos digitales:

• Portal de clientes con 1.243 usuarios registrados
• Biblioteca de documentación técnica
• Sistema de soporte de chat en vivo
• Plataformas de actualización de firmware de productos

Plataforma digital	2023 métricas
Usuarios del portal de clientes	1,243
Interacciones de soporte digital mensual	2,187
Tiempo de respuesta de soporte digital promedio	37 minutos

Strata Skin Sciences, Inc. (SSKN) - Modelo de negocios: canales

Fuerza de ventas directa dirigida a clínicas de dermatología

A partir del cuarto trimestre de 2023, Strata Skin Sciences mantiene un equipo de ventas dedicado de 27 representantes de ventas directas dirigidas específicamente a clínicas de dermatología en los Estados Unidos.

Métrico de canal de ventas	Valor
Representantes de ventas directas totales	27
Cobertura geográfica	Estados Unidos
Llamada promedio de ventas por representante por semana	12-15

Distribuidores de dispositivos médicos

Strata Skin Sciences utiliza una red de 14 distribuidores de dispositivos médicos para expandir el alcance del producto.

• Regiones de distribución primaria: América del Norte
• Recuento de socios de distribución: 14
• Ingresos promedio del canal de distribución: $ 3.2 millones anuales

Plataformas de información de productos en línea

Los canales digitales incluyen el sitio web de la compañía y las plataformas de tecnología médica especializada.

Canal en línea	Tráfico web mensual
Sitio web de la empresa	42,000 visitantes únicos
Plataformas de tecnología médica	18,500 visitantes únicos

Exposiciones de conferencia médica

Strata participa en 6-8 conferencias de dermatología principales anualmente.

• Participación anual de la conferencia: 6-8 eventos
• Generación de leads promedio de la conferencia: 150-200 clientes potenciales
• Gastos estimados de marketing de conferencia: $ 275,000 anualmente

Eventos de redes profesionales de atención médica

Los eventos de redes específicos respaldan estrategias directas de ventas y construcción de relaciones.

Métrica del evento de redes	Valor
Eventos anuales de redes	12-15
Asistentes promedio por evento	75-100 profesionales de la salud
Tasa de conversión de eventos	8-12%

Strata Skin Sciences, Inc. (SSKN) - Modelo de negocio: segmentos de clientes

Clínicas de dermatología y prácticas médicas

A partir del cuarto trimestre de 2023, Strata Skin Sciences sirve aproximadamente 1,200 clínicas de dermatología en los Estados Unidos.

Característica de segmento	Punto de datos
Tamaño total del mercado	3.450 prácticas de dermatología en los Estados Unidos
Penetración del mercado	34.8% de las prácticas de dermatología total
Ingresos anuales promedio por clínica	$ 157,000 de líneas de productos de estratos

Centros de tratamiento estético

Los estratos se dirigen a 850 centros de tratamiento estético en todo el país.

• Concentración en las principales áreas metropolitanas
• Centrado en proveedores de tratamiento estético de alta gama
• Ingresos medios del centro: $ 1.2 millones anuales

Prácticas de cirugía plástica

Los estratos sirven 675 prácticas de cirugía plástica en 2024.

Métrico de segmento	Datos cuantitativos
Total de prácticas de cirugía plástica de EE. UU.	5.600 prácticas
Cobertura del mercado de estratos	12.05% de las prácticas totales
Gasto promedio de productos	$ 98,500 por práctica anualmente

Hospitales con departamentos de dermatología

Strata tiene asociaciones con 210 departamentos de dermatología del hospital.

• Principalmente centros médicos académicos
• Presupuesto promedio del departamento del hospital: $ 425,000
• Distribución geográfica en 47 estados

Instituciones de investigación médica

Strata colabora con 95 instituciones de investigación médica.

Tipo de institución de investigación	Número de asociaciones
Centros de investigación universitarios	62
Fundamentos de investigación privada	33
Valor de subvención de investigación promedio	$ 275,000 por institución

Strata Skin Sciences, Inc. (SSKN) - Modelo de negocio: Estructura de costos

Inversiones de investigación y desarrollo

Para el año fiscal 2023, Strata Skin Sciences reportó gastos de I + D de $ 5.3 millones, lo que representa el 19.2% de los ingresos totales.

Año	Gastos de I + D	Porcentaje de ingresos
2023	$5,300,000	19.2%
2022	$4,800,000	17.6%

Costos de fabricación y producción

Los gastos de fabricación totales para 2023 fueron de $ 8.7 millones, con componentes de costo clave que incluyen:

• Adquisición de materia prima: $ 3.2 millones
• Trabajo directo: $ 2.5 millones
• Mantenimiento del equipo: $ 1.6 millones
• Sobrecoss de la instalación: $ 1.4 millones

Gastos de ventas y marketing

Los gastos de ventas y marketing para 2023 totalizaron $ 7.9 millones, lo que representa el 28.6% de los ingresos totales.

Categoría de gastos	Cantidad
Compensación del personal de ventas	$ 3.6 millones
Campañas de marketing	$ 2.3 millones
Participación en la feria y la conferencia	$ 1.2 millones
Marketing digital	$ 0.8 millones

Gastos de cumplimiento regulatorio

Los costos de cumplimiento regulatorio para 2023 ascendieron a $ 2.1 millones, que incluyen:

• Cumplimiento de la FDA: $ 1.2 millones
• Garantía de calidad: $ 0.5 millones
• Documentación del ensayo clínico: $ 0.4 millones

Mantenimiento de la infraestructura tecnológica

Los gastos de mantenimiento de la infraestructura tecnológica para 2023 fueron de $ 1.5 millones, desglosados ​​de la siguiente manera:

• Sistemas y software de TI: $ 0.7 millones
• Ciberseguridad: $ 0.4 millones
• Actualizaciones de hardware: $ 0.3 millones
• Servicios en la nube: $ 0.1 millones

Strata Skin Sciences, Inc. (SSKN) - Modelo de negocios: flujos de ingresos

Venta de dispositivos médicos

Para el año fiscal 2023, Strata Skin Sciences informó ventas de dispositivos médicos de $ 23.4 millones, específicamente de sus sistemas láser de icono y Excel utilizados en procedimientos dermatológicos.

Tipo de dispositivo	Ingresos anuales	Cuota de mercado
Sistema láser ícono	$ 14.2 millones	60.7%
Sistema láser de Excel	$ 9.2 millones	39.3%

Contratos de mantenimiento de equipos recurrentes

Los estratos generaron $ 5.6 millones en ingresos de contratos de mantenimiento anuales para 2023.

Consumibles y piezas de repuesto

Los ingresos por los consumibles y las piezas de repuesto totalizaron $ 7.8 millones en 2023.

• Piezas de mano láser: $ 3.2 millones
• Componentes de calibración: $ 2.1 millones
• Accesorios de protección: $ 1.5 millones
• Partes misceláneas: $ 1.0 millones

Tarifas de servicio de capacitación y apoyo

Los estratos generaron $ 3.5 millones a partir de servicios de capacitación y apoyo en 2023.

Licencias de tecnologías propietarias

Los ingresos por licencias de tecnología fueron de $ 2.1 millones para el año fiscal 2023.

Categoría de licencias	Ganancia
Licencias de tecnología dermatológica	$ 1.4 millones
Licencia de procedimiento estético	$ 0.7 millones

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Value Propositions

The value proposition STRATA Skin Sciences, Inc. offers centers on shifting the financial burden and risk from the clinic to a performance-based model, while delivering clinically superior, non-systemic treatment options.

For partner clinics, the core offering is the Partnership Program, which utilizes a fee-per-treatment cost structure instead of requiring upfront capital expenditure for equipment purchase. This model directly reduces the initial financial risk for providers adopting the XTRAC excimer laser technology.

The clinical superiority of the XTRAC system is validated by recent data, particularly when used in combination therapies. For plaque-type psoriasis, a study combining the XTRAC 308nm Excimer Laser with 0.1% tacrolimus ointment showed markedly superior results compared to topical monotherapy:

Treatment Group	Mean PASI Reduction (Initial to Final)	Statistical Significance
Control (Topical Monotherapy)	Mean PASI dropped from 18.62 to 5.23	p < 0.01 vs. Observation
Observation (Topical + XTRAC)	Mean PASI dropped from 18.36 to 3.30	Statistically significant difference

Furthermore, the treatment is inherently non-invasive and targeted, offering fewer side effects than systemic drugs, a key differentiator in chronic condition management. This is reinforced by data showing promising results for vitiligo treatment using the Excimer Laser combined with a Janus kinase inhibitor, demonstrating superior safety and unprecedented response rates.

STRATA Skin Sciences, Inc. actively helps clinics maximize the revenue potential of existing assets through the Elevate 360 (E360) consulting platform. Since the start of 2025, 99 of the approximately 838 clinics operating under an XTRAC usage agreement have enrolled, reporting an average 7% year-over-year revenue increase for those businesses completing the review.

One case study illustrated the operational impact: a partner clinic group increased its revenue contribution to STRATA Skin Sciences, Inc. from $10,500 in the first half of 2024 to $61,800 in the first half of 2025, while expanding from 2 clinics to 9 clinics after adopting E360 in Q3 2024.

Market access is being significantly broadened by the American Medical Association's revision to CPT codes 96920-96922. This change expands reimbursement eligibility beyond psoriasis to include multiple inflammatory and autoimmune skin conditions. This is expected to unlock access for over 30 million U.S. patients, a threefold expansion from the roughly 10 million psoriasis patients previously covered. STRATA Skin Sciences, Inc. is working to make these expanded indications reimbursable as early as the 2026 rule cycle via temporary CMS codes, aiming for the official January 1, 2027, effective date.

Here's a quick look at some key operational and financial metrics as of late 2025:

• Number of U.S. partner clinics under XTRAC usage agreement: Approximately 838.
• Average gross billings per device (Q3 2025): $5,981.
• Q3 2025 Total Revenue: $6.9 million.
• Q3 2025 Gross Margin: 60%.
• Cash and cash equivalents (End of Q3 2025): $7.1 million.
• Potential addressable patient population unlocked by CPT expansion: Over 30 million.

The expected expansion in addressable market size, combined with the recurring revenue stream from the fee-per-treatment model, underpins the long-term value proposition for providers utilizing the E360 support structure.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Customer Relationships

The relationship STRATA Skin Sciences, Inc. maintains with its key customer segments-physician practices utilizing their devices and the end-patients-is structured around high-touch support and direct patient acquisition initiatives.

The foundation of practice support involves personnel dedicated to service and account management, which underpins the consultative offerings. This structure is designed to ensure optimal utilization of their capital equipment, such as the XTRAC excimer laser systems.

High-touch, consultative support via the Elevate 360 program.

The Elevate 360 (E360) consulting services platform is a core component of the relationship strategy, focusing on implementing best practices in marketing, reimbursement optimization, and patient retention for partner clinics. Since the start of 2025, 99 out of approximately 844 clinics operating under STRATA Skin Sciences, Inc.'s XTRAC usage agreement have enrolled in this program. Participating clinics have demonstrated an average 7% year-over-year growth. This consultative approach directly impacts the revenue stream flowing back to STRATA Skin Sciences, Inc.

A specific case study illustrates the impact of this high-touch support:

Metric	H1 2024 (Pre-E360)	H1 2025 (Post-E360 Implementation)	Change
STRATA Revenue Contribution from Partner	$10,500	$61,800	489% Increase
Clinic Locations Covered	2	9	7 Additional Clinics

This partner began implementing E360 in Q3 2024.

Partnership Program offering on-site training and co-op advertising.

The Partnership Program, which often utilizes a fee-per-treatment cost structure rather than outright equipment purchases, integrates the E360 consulting services, which include turn-key marketing solutions and business system optimization. This relationship focus is also reflected in device performance metrics. For the second quarter of 2025, the average gross billings per device reached $5,512, showing a 2.7% increase over the comparable prior-year period. Furthermore, the installed base for the TheraClearX Acne Therapy System reached 160 devices in the U.S. by the end of Q1 2025, up from 104 devices at the end of Q1 2024.

Key elements of the support structure include:

• Optimizing the end-to-end treatment process.
• Securing reimbursement and patient insurance benefits.
• Scheduling follow-up patient visits for retention.

Direct engagement with patients through DTC marketing efforts.

STRATA Skin Sciences, Inc. actively engages patients directly to drive appointment volume for its partners. The company's direct-to-consumer (DTC) strategy is a key driver of patient acquisition. In the first quarter of 2025, DTC marketing efforts generated over 1,000 appointments. This, combined with organic growth, resulted in the number of unique patients for whom STRATA Skin Sciences, Inc. handled insurance benefits increasing by 33% year-over-year in Q1 2025. The number of patients submitted for reimbursement in Q1 2025 increased 138% year-over-year, with pre-authorized rates exceeding 85%.

The President and CEO noted in November 2025 that the company continues to strategically expand its patient pool through these DTC efforts while strengthening practice partners through consulting services.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Channels

You're looking at how STRATA Skin Sciences, Inc. gets its products and services to the customer, which is a mix of direct engagement and partner reliance. Here's the breakdown of the channels they use, grounded in the latest figures we have through Q3 2025.

Direct sales force for U.S. dermatology practices

The core U.S. channel relies on a direct engagement model, primarily through the Partnership Program, which focuses on recurring revenue rather than outright equipment sales for the XTRAC system. This program provides equipment, training, maintenance, and co-op advertising support to clinics. The structure is based on a fee per treatment cost, not just an equipment purchase. As of June 30, 2025, STRATA Skin Sciences, Inc. reported that 844 U.S. dermatology clinics were utilizing the XTRAC excimer laser technology under this partnership program. This is out of an estimated total of around 1,200 U.S. clinics using excimer laser therapy subject to CPT codes 96920 - 96922. The TheraClearX device, aimed at acne, also has a direct component; its installed base in the U.S. reached 160 devices by the end of Q1 2025, up from 104 devices in Q1 2024. The XTRAC system under the recurring procedures model is placed in the office, and fees are charged per procedure or periodically. The company is working to grow the number of clinics, especially those owned by private equity backed national accounts, which present a potential expansion of over 2,000 additional clinics.

Here's a quick look at the U.S. installed base metrics:

Metric	Value as of Late 2025 Data Point	Reference Period
Clinics using XTRAC under Partnership Program	844	As of June 30, 2025
Total U.S. Clinics Using Excimer Laser Therapy (CPT 96920-96922)	Around 1,200	As of October 2025 data
TheraClearX Installed Base (US)	160 devices	End of Q1 2025
TheraClearX Installed Base (US)	104 devices	Q1 2024

International distribution partners for global sales

Global sales are heavily reliant on exclusive distribution partners, a channel that historically contributed significantly to the top line. International revenue in Q1 2025 was $2.5 million, marking an 8% increase YoY, and accounted for 36% of total revenue. This contrasts with Q2 2025 equipment revenue from international business, which decreased 18% YoY. The company has renewed key agreements, such as the three-year extensions with distributors in China and Japan, which collectively accounted for 46% of total international revenue in 2023. The Korean agreement with Kosmo Meditech (Cutech) is extended through December 31, 2026. A risk to this channel is the potential impact of tariffs, with outbound rates into non-US markets like Asia potentially reaching 145% on free parts under warranty, which could lead to a "meaningful reduction in international revenue."

Direct-to-Consumer (DTC) digital and traditional advertising

STRATA Skin Sciences, Inc. actively uses DTC marketing to drive patient volume to its partner clinics, which in turn boosts recurring revenue. This strategy is focused on geographies where partner clinics are effective at converting leads. In Q1 2025, DTC efforts generated over 1,000 patient appointments. The efficiency of this channel improved significantly in the second half of 2025, with a much lower cost per acquisition driven by better media costs and conversion rates. The impact on patient volume was clear:

• DTC drove 32% more unique Psoriasis patients YoY in Q1 2025.
• DTC drove 128% more unique Acne patients YoY in Q1 2025.
• Overall unique patients for whom STRATA handled insurance benefits increased 33% YoY in Q1 2025.

Company website and investor relations for corporate communication

The corporate communication channel primarily serves investors and stakeholders, providing updates on financial health and strategic positioning. For the third quarter of 2025, the company reported total revenue of approximately $6.9 million, with a gross margin that remained stable at 60%. The company ended Q3 2025 with $7.1 million in cash, following $6.0 million in cash and cash equivalents at June 30, 2025. The latest analyst consensus reflected a Hold rating with a price target of $1.50. The company is also using IR communications to highlight strategic legal wins, such as the litigation against LaserOptek, which is expected to bring in over $1 million in annualized capital and recurring revenue from recaptured clients. The company's ability to secure temporary CMS codes is also communicated here, aiming to accelerate access for expanded indications as early as the 2026 rule cycle.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Customer Segments

You're looking at the specific groups STRATA Skin Sciences, Inc. targets with its medical devices and recurring revenue streams as of late 2025. It's a mix of clinical providers and the patients they treat, with a clear focus on maximizing utilization of installed equipment.

U.S. Dermatology and Plastic Surgery Practices

These practices form the core of the recurring revenue base, primarily through the use of the XTRAC system for chronic conditions and the newer TheraClearX for acne. STRATA Skin Sciences, Inc. focuses on optimizing the performance of the existing installed base through programs like Elevate 360.

• U.S. partner clinics operating under XTRAC usage agreement (Q3 2025): approximately 838 clinics.
• Clinics enrolled in the Elevate 360 program since the beginning of 2025: 99.
• Average gross billings per XTRAC device for all U.S. partner clinics (Q3 2025): $5,981.
• Average net revenue per domestic XTRAC system (Q1 2025): $4,776.
• Domestic XTRAC Gross Recurring Billings (Q3 2025): $4.8 million.

The company is actively managing its installed base; for example, the domestic installed base of XTRAC units was reported at 873 units in Q2 2025, following a strategic removal of underperforming units from the previous count of 882 in Q2 2024.

Metric	Value / Period	Source Context
Total Private Equity-Backed Groups Partnered	48 groups	Data point from Q1 2024, used for context on partnership scale.
Total Clinic Locations within PE Groups	2,482 locations	Data point from Q1 2024, used for context on partnership scale.
XTRAC Devices Deployed Across PE Groups	386 devices	Data point from Q1 2024, used for context on partnership scale.
TheraClearX Devices Deployed Across PE Groups	62 devices	Data point from Q1 2024, used for context on partnership scale.
TheraClearX Installed Base in US (Q1 2025)	160 devices	Latest reported installed base for TheraClearX.

International Clinics and Medical Spas

This segment shows strong growth momentum, though it is subject to external factors like tariff uncertainty. STRATA Skin Sciences, Inc. is also establishing new commercial models internationally, such as in Mexico.

• International revenue growth (Q1 2025 vs Q1 2024): 8%.
• International revenue as a percentage of total revenue (Q1 2025): 36%.
• International equipment sales growth (Q1 2025 vs Q1 2024): 13%.
• Average patient payment for an acne visit in Mexico: equivalent of about $140.

The company has achieved regulatory clearance in Mexico from COFEPRIS for its TheraClearX device as of Q3 2025, with plans to announce a significant number of placements there by the end of 2025.

Patients with Chronic Dermatologic Conditions (psoriasis, vitiligo, eczema)

These patients are primarily served through the established XTRAC platform, which is positioned as the gold standard for conditions like psoriasis and vitiligo. Direct-to-Consumer (DTC) marketing is directly impacting patient volume.

• Unique Psoriasis patients driven by DTC efforts (Q1 2025): 32% more than the prior year period.
• Unique patients for whom STRATA handled insurance benefits (Q1 2025): increased 33% year-over-year.

Clinical validation continues to support this segment, with multiple new peer-reviewed publications in Q3 2025 validating XTRAC for vitiligo in combination therapy with JAK inhibitors and for localized atopic dermatitis.

Patients with Mild-to-Moderate Acne (via TheraClearX)

The TheraClearX device targets the most common skin condition in dermatology, offering a reimbursable option to practices. The focus here is on driving procedure volume and device utilization.

Metric	Value / Period	Context
TheraClearX Patients Submitted for Reimbursement (Q1 2025)	1,000 patients	Represents a 138% increase from 438 in Q1 2024.
TheraClearX Pre-authorization Rates	Exceed 85%	Indicates strong payer acceptance.
Annual Procedures to Breakeven for One Device	200 procedures	Equivalent to about 50 procedures per quarter.
Annual Revenue Breakeven for One Device	Approximately $9,000	The financial threshold for device profitability.
Unique Acne Patients driven by DTC (Q1 2025)	128% more than prior year period	Shows strong demand generation from DTC efforts.
Target TheraClearX Device Deployments (End of 2025)	200 devices	The company's stated deployment goal for the year.

The company is executing a strategy to increase TheraClearX placements within existing XTRAC partner clinics, aiming for a total installed base of 200 devices by the end of 2025.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Cost Structure

You're looking at the cost side of the STRATA Skin Sciences, Inc. (SSKN) engine as of late 2025. Honestly, cost control looks like a major theme, especially when you see how they managed expenses coming out of Q1.

The overall picture for the third quarter of 2025 shows that Total Operating Expenses were $5.4 million, which is a meaningful reduction from the $6.9 million reported in the prior-year period. This reduction helped push the company to a slightly positive Adjusted EBITDA for Q3 2025, compared to negative $240,000 in Q3 2024.

Here's a quick look at how the major operating expense buckets stacked up in Q3 2025 versus the cost-cutting quarter of Q1 2025, where they were clearly tightening the belt:

Expense Category	Q3 2025 (in thousands)	Q1 2025 (in thousands)
Selling and Marketing	$3,201	$2,993
General and Administrative (G&A)	$2,668	$2,573
Engineering and Product Development	Not explicitly provided for Q3 2025	$96
Total Operating Expenses	$5,357 (Excluding Other)	$5,662

The Selling and Marketing expenses in Q3 2025 were $3,201 thousand. You'll note the CEO mentioned strategically expanding the patient pool through Direct-to-Consumer (DTC) efforts, so you'd expect that line item to reflect that spend, even as they manage overall costs.

For General and Administrative (G&A) costs, the Q3 2025 figure was $2,668 thousand. That Q3 number is easier to digest than Q3 2024, which included a one-time $1.8 million accrual for New York State sales tax. Also, keep an eye on legal fees here; the company noted positive developments in the ongoing lawsuit against LaserOptek, which is a cost that can swing G&A depending on litigation phases.

The aggressive cost management in Engineering and Product Development is clear from the first quarter data. For Q1 2025, these expenses were down 60% versus the prior-year period, driven by reduced headcount and project-specific consulting. The actual spend in Q1 2025 for this category was only $96 thousand.

Regarding the cost tied to recurring revenue, STRATA Skin Sciences operates on a Partnership Program that includes a fee per treatment cost structure. This structure covers the use of the device, on-site training, and crucially, service and maintenance of the equipment. In Q3 2025, the Global recurring revenue component was strong at $5.5 million, which increased 3% year-over-year. The cost associated with generating this revenue would include the direct costs of servicing those devices and providing ongoing support, which is embedded within the overall operating expenses.

• Cost of recurring revenue is covered by the fee per treatment model, which includes service and maintenance.
• Global recurring revenue in Q3 2025 was $5.5 million.
• Selling and Marketing expenses in Q3 2025 were $3,201 thousand.
• G&A costs in Q3 2025 were $2,668 thousand.
• Engineering and Product Development expenses were down 60% in Q1 2025.

Finance: draft 13-week cash view by Friday.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Revenue Streams

You're looking at the core ways STRATA Skin Sciences, Inc. brings in cash, which really boils down to two main buckets as of late 2025: the ongoing services and the one-time sales of hardware. It's important to see how these pieces fit together to form the total picture.

The recurring side of the business, which includes revenue from treatment codes and service fees, is the foundation. For the third quarter of 2025, STRATA Skin Sciences reported $5.5 million in Global Recurring Revenue. This stream saw a modest increase, with net U.S. recurring XTRAC revenue up 2.8% and gross code sales up 4.1% for the period.

The other major component is equipment sales, which is the revenue from selling the actual devices. For Q3 2025, Equipment Revenue was $1.4 million. This segment experienced a significant year-over-year drop, decreasing 60% compared to the prior year period.

When you put those two streams together, the Total Revenue for STRATA Skin Sciences for the third quarter of 2025 was $6.9 million. This total was down about 20% compared to Q3 2024, largely due to the softness in international equipment sales.

Here's a quick breakdown of how those revenue components stacked up for the quarter:

Revenue Stream Component	Q3 2025 Amount
Global Recurring Revenue (Treatment Codes/Service Fees)	$5.5 million
Equipment Revenue (Device Sales)	$1.4 million
Total Revenue	$6.9 million

Drilling down into the utilization of the installed base, which directly impacts recurring revenue, we see positive trends in efficiency. The Average gross billings per domestic XTRAC device was $5,981 in Q3 2025. Honestly, that figure represents the highest average gross billings per device since the fourth quarter of 2022, showing increased utilization across the 838 U.S. partner clinics.

The revenue streams are also influenced by non-operating items, like legal outcomes. While the core business is recurring and equipment sales, there is potential future upside from litigation. For instance, in Q3 2025, STRATA Skin Sciences booked settlement gains for roughly $680,000, which contributed to lower operating expenses for the quarter.

You should keep an eye on the following factors that influence these revenue streams:

• Expansion of CPT codes for reimbursement, which is expected to triple the covered patient population in the U.S.
• The success of strategic device placements, such as the clearance received in Mexico for the TheraClearX device.
• The ongoing lawsuit against LaserOptek, which has positive developments that could lead to increased revenue or damages collection.
• The performance of the Elevate 360 program, which has shown significant revenue contribution increases from participating partners.

Finance: draft 13-week cash view by Friday.